$250B of U.S. Health Costs Could Be Tied to Exposure to Chemicals in Plastics
16 Jan 2024
Clinical Result
TUESDAY, Jan. 16, 2024 -- Plastics exposure contributes substantially to disease costs in the United States, according to a study published online Jan. 11 in the Journal of the Endocrine Society.
Leonardo Trasande, M.D., from the NYU Grossman School of Medicine in New York City, and colleagues calculated the attributable disease burden and cost due to chemicals used in plastic materials in 2018.
The researchers identified plastic-related fractions of 97.5 percent for bisphenol A, 98 percent for di-2-ethylhexylphthalate, 100 percent for butyl phthalates and benzyl phthalates, 98 percent for polybrominated diphenylether (PBDE)-47, and 93 percent for perfluoroalkyl substances (PFAS). In a sensitivity analysis, the total estimate of plastic-attributable disease burden in 2018 ranged from $226 billion to $289 billion, with the majority of these costs arising from PBDE exposure. Additionally, an estimated $66.7 billion was due to phthalate exposure and $22.4 billion was due to PFAS exposure.
"Plastics contribute substantially to disease and associated social costs in the United States, accounting for 1.22 percent of the gross domestic product. The costs of plastic pollution will continue to accumulate as long as exposures continue at current levels," the authors write. "Actions through the Global Plastics Treaty and other policy initiatives will reduce these costs in proportion to the actual reductions in chemical exposures achieved."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.